NASDAQ:JAGX

Jaguar Health - JAGX Stock Forecast, Price & News

$0.16

0.00 (0.00%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.16
▼
$0.17
50-Day Range: $0.16
▼
$0.33
52-Week Range: $0.15
▼
$2.66

Volume: 2.85 million shs
Average Volume: 3.42 million shs
Market Capitalization: $18.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Jaguar Health MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
10.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.22
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.67) to ($0.36) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

Medical Sector

979th out of 1,093 stocks

Pharmaceutical Preparations Industry

484th out of 547 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Jaguar Health.

4.0

Short Interest

Percentage of Shares Shorted
10.47% of the float of Jaguar Health has been sold short.
Short Interest Ratio / Days to Cover
Jaguar Health has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Jaguar Health has recently decreased by 9.44%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Jaguar Health does not currently pay a dividend.
Dividend Growth
Jaguar Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for JAGX.

2.9

News and Social Media Coverage

News Sentiment
Jaguar Health has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Jaguar Health this week, compared to 2 articles on an average week.
Search Interest
Only 12 people have searched for JAGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Jaguar Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -79% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jaguar Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.28% of the stock of Jaguar Health is held by insiders.
Percentage Held by Institutions
Only 7.40% of the stock of Jaguar Health is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Jaguar Health are expected to grow in the coming year, from ($0.67) to ($0.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Jaguar Health is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Jaguar Health is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Jaguar Health has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Jaguar Health (NASDAQ:JAGX) Stock

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

JAGX Stock News Headlines

September 29, 2022 | msn.com

Jaguar Land Rover announces ambitious plan to train thousands

September 29, 2022 | finance.yahoo.com

Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other Pathogens

September 27, 2022 | americanbankingnews.com

Jaguar Health (NASDAQ:JAGX) Coverage Initiated at StockNews.com

September 22, 2022 | finance.yahoo.com

Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th

September 9, 2022 | msn.com

Watch This Jaguar XJR-12 Scream Around Paul Ricard

August 30, 2022 | msn.com

Jaguar Health Seeks FDA Nod For Cholera Candidate Study

August 30, 2022 | finance.yahoo.com

Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera

August 27, 2022 | finanznachrichten.de

Jaguar Health, Inc.: Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream

August 25, 2022 | finance.yahoo.com

Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream

August 24, 2022 | finanznachrichten.de

Jaguar Health, Inc.: Jaguar Health Provides Company Updates and Reports 2022 Second Quarter Financials

August 23, 2022 | investing.com

Jaguar Health Reports Q2 Revenue of $2.9M, Provides Company Updates

August 23, 2022 | finance.yahoo.com

Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review

August 19, 2022 | finanznachrichten.de

Jaguar Health, Inc.: Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

August 19, 2022 | finance.yahoo.com

Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

August 17, 2022 | finance.yahoo.com

Jaguar Health to Host Investor Webcast Monday, August 22nd at 8:30 AM Eastern Time Regarding Q2 2022 Financials & Corporate Updates

August 10, 2022 | finance.yahoo.com

Gallup Survey Estimates Nearly 30 Million U.S. Dog Owners Have Experienced Canine Cancer, with Many Saying it Negatively Impacted Their Own Quality of Life

August 9, 2022 | finance.yahoo.com

Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemotherapy-Induced Diarrhea

August 4, 2022 | msn.com

This Rare, Street-Legal Jaguar XJR-15 Could Sell for up to $1.4 Million at Auction

July 6, 2022 | uk.investing.com

Short Volatility Alert: Jaguar Health, Inc.

July 5, 2022 | finance.yahoo.com

Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions

June 29, 2022 | seekingalpha.com

Jaguar stock rises on license deal with SynWorld for Canalevia in China

June 29, 2022 | finance.yahoo.com

Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China

June 24, 2022 | benzinga.com

Thinking about buying stock in Blue Hat Interactive, Vroom, Revlon, Roblox, or Jaguar Health?

June 22, 2022 | finance.yahoo.com

Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi

June 21, 2022 | finance.yahoo.com

Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

JAGX Company Calendar

Last Earnings: 8/22/2022
Today: 10/01/2022
Next Earnings (Estimated): 11/16/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:JAGX
CUSIP: N/A
CIK: 1585608
Web: www.jaguaranimalhealth.com
Phone: (415) 371-8300
Fax: N/A
Employees: 52
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-52,600,000.00
Net Margins: -652.35%
Pretax Margin: -654.84%
Return on Equity: -486.62%
Return on Assets: -100.06%

Debt

Debt-to-Equity Ratio: 8.47
Current Ratio: 1.02
Quick Ratio: 0.73

Sales & Book Value

Annual Sales: $4.34 million
Price / Sales: 4.31
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.23 per share
Price / Book: 0.68

Miscellaneous

Outstanding Shares: 120,040,000
Free Float: 118,501,000
Market Cap: $18.73 million
Optionable: Not Optionable
Beta: 1.65

Key Executives

Ms. Lisa A. Conte (Age 63)
Founder, CEO, Pres & Director
Comp: $722.54k

Mr. Jonathan S. Wolin CPA (Age 60)
J.D., M.B.A., Chief of Staff, Chief Compliance Officer & Gen. Counsel
Comp: $478.72k

Mr. Ian H. Wendt M.B.A. (Age 54)
Chief Commercial Officer
Comp: $431.55k

Dr. Steven R. King Ph.D. (Age 64)
Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.
Comp: $452.61k

Ms. Carol R. Lizak (Age 58)
Chief Financial Officer

Dr. Pravin R. Chaturvedi Ph.D. (Age 59)
Chief Scientific Officer & Chair of Scientific Advisory Board

Mr. Peter Hodge
Sr. Director of Investor Relations, Bus. Devel. & Special Events

Dr. Karen J. Brunke Ph.D.
Exec. VP of Corp. & Bus. Devel.

Mr. David Sesin
Chief Manufacturing Officer

Dr. Michael K. Guy D.V.M.
M.S., Ph.D., VP of Preclinical & Nonclinical Studies

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JAGX Stock - Frequently Asked Questions

How have JAGX shares performed in 2022?: Jaguar Health's stock was trading at $1.04 at the beginning of 2022. Since then, JAGX stock has decreased by 85.0% and is now trading at $0.1560.
View the best growth stocks for 2022 here.
When is Jaguar Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 16th 2022.
View our JAGX earnings forecast.
How were Jaguar Health's earnings last quarter?: Jaguar Health, Inc. (NASDAQ:JAGX) announced its quarterly earnings results on Monday, August, 22nd. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. The biotechnology company had revenue of $2.92 million for the quarter. Jaguar Health had a negative net margin of 652.35% and a negative trailing twelve-month return on equity of 486.62%.
When did Jaguar Health's stock split?: Jaguar Health's stock reverse split before market open on Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).
When did Jaguar Health IPO?: (JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
What is Jaguar Health's stock symbol?: Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."
How do I buy shares of Jaguar Health?: Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Jaguar Health's stock price today?: One share of JAGX stock can currently be purchased for approximately $0.16.
How much money does Jaguar Health make?: Jaguar Health (NASDAQ:JAGX) has a market capitalization of $18.73 million and generates $4.34 million in revenue each year. The biotechnology company earns $-52,600,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.
How can I contact Jaguar Health?: Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The official website for the company is www.jaguaranimalhealth.com. The biotechnology company can be reached via phone at (415) 371-8300.

This page (NASDAQ:JAGX) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Jaguar Health - JAGX Stock Forecast, Price & News

Jaguar Health MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows